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Abstract: The authors have manufactured a novel rabbit foldable capsular vitreous body (FCVB). 
The aim of this study was to determine whether this rabbit FCVB can release levofloxacin 
in vitro and in vivo, and to evaluate the release characteristics. In vitro, the rabbit FCVB with 
levofloxacin 500 µg/mL was immersed in cups of modified Franz diffusion cells. Following this, 
200 µL of liquid was aspirated at intervals from 10 minutes to 24 hours. In vivo, the FCVB with 
levofloxacin was implanted into the right eyes of five rabbits. After implantation, the aqueous 
humor was aspirated on days 1, 7, 14, 28, and 56. The levofloxacin concentrations in the cups 
and aqueous humor samples were detected by high-performance liquid chromatography–tandem 
mass spectrometry. The FCVB was observed under a scanning electron microscope. The results 
showed that the released levofloxacin was stabilized at 20 ng/mL at time points from 10 minutes to 
24 hours in vitro. In vivo, levofloxacin concentrations in the aqueous humor were 132, 50, 39, 11, 
and 15 ng/mL on days 1, 7, 14, 28, and 56, respectively. In the FCVB capsules, 300 nm apertures 
were observed. These results suggest the rabbit FCVB released levofloxacin stably in vitro and 
sustainably in vivo. This study provides a novel combined approach, with the FCVB as a vitreous 
substitute and drug delivery system for the treatment of bacterial endophthalmitis.
Keywords: drug delivery system, high-performance liquid chromatography–tandem mass 
spectrometry, vitreous substitute, bacterial endophthalmitis
Introduction
Bacterial endophthalmitis is a rare but catastrophic complication of intraocular surgery 
and penetrating injuries.1 The overall incidence of endophthalmitis following cataract 
surgery in the United States is about 0.1%.2 Endophthalmitis occurs at a much higher 
rate with penetrating ocular injuries than with surgery: from 2% to 16% of eyes 
develop microbial endophthalmitis.3 Retinal detachment is one of the most serious 
complications of endophthalmitis and it occurs with an incidence rate of from 4% 
to 21%.1 The visual outcome is poor, with most cases leading to blindness in the 
affected eye.4 Many patients have extraocular foci of infection, with an associated 
mortality rate of 5%.4
As for the drugs used for therapy, an intravitreal first-line drug therapy is 
recommended: vancomycin (1.0 mg/0.1 mL) to cover Gram-positive microorganisms 
and ceftazidime (2.25 mg/0.1 mL) to cover Gram-negative microorganisms.5 However, 
ceftazidime is physically incompatible with vancomycin, and it is therefore necessary 
to inject the two antibiotics from separate syringes to avoid precipitation of the drugs.6,7 
There has been a recent drive in ophthalmology to explore the clinical potential of 
fluoroquinolones.8 Levofloxacin is a third-generation fluoroquinolone and it is the International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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antibacterially active L-isomer of the racemate ofloxacin. 
Levofloxacin has activity against both Gram-positive and 
Gram-negative bacteria.9 Various studies have been carried 
out to determine the safety and efficacy of levofloxacin 
as a treatment for conjunctivitis and keratitis10,11 and of 
intravitreal levofloxacin in Staphylococcus epidermidis 
endophthalmitis.8,12
As the route for administration, systemic antibiotics 
have been used concurrently for bacterial endophthalmitis.13 
However, the blood-ocular barrier prevents the entrance and 
subsequent activity of most systemic antimicrobial and anti-
inflammatory drugs.3 The recommended management of 
bacterial endophthalmitis includes direct injections of antibi-
otics into the vitreous.2 However, this method of treatment is 
fraught with risks. Direct intravitreal injections increase the 
risk of retinal detachments, cataracts, vitreous hemorrhage, 
and endophthalmitis.14 Photoreceptors and other cells of the 
retina are exquisitely sensitive to the antimicrobial agents 
and the biochemical pathways necessary for vision may 
potentially be disrupted.3 An intravitreal drug delivery system 
(DDS) is a feasible solution to this unique dilemma.15,16
In previous studies, the authors have proposed a new 
strategy to replace the natural vitreous body using a novel 
foldable capsular vitreous body (FCVB).17–21 The FCVB 
consisted of a thin, vitreous-shaped capsule with a tube-valve 
system created using a computer and industrial technology. 
After the foldable installation into the eye, a balanced salt 
solution was injected to inflate the capsule and support the 
retina and control the intraocular pressure through the tube-
valve system.17 Interestingly, the FCVB changes the refraction 
very little compared with silicone oil and heavy silicone 
oil, based on the Gullstrand-Emsley and Liou-Brennan 
schematic eyes.18 Reports from the Chinese State Food and 
Drug Administration (No. G20080656) and additional tests 
according to guidelines of the International Organization for 
Standardization show that the FCVB has good mechanical, 
optical, and biocompatible properties.19 An exploratory 
clinical trial conducted at the Zhongshan Ophthalmic Center, 
Sun Yat-sen University, China, showed that the FCVB was a 
flexible, effective, and safe vitreous substitute over a 3-month 
implantation period in human eyes.20 Moreover, the FCVB 
can sustainably and mechanically release dexamethasone 
sodium phosphate (DexP) and may be used as an intravitreal 
DDS for DexP.21 The purpose of this article is to evaluate 
whether the rabbit FCVB could release levofloxacin in vitro 
and in vivo and whether it could provide a combined therapy 
strategy as a vitreous substitute and DDS for the treatment 
of bacterial endophthalmitis.
Material and methods
Basic materials and fabrication  
of the rabbit FcVB
The rabbit FCVB was fabricated with tailor-made modified 
liquid silicone rubber. The basic material, Dow Corning 
Class VI elastomer, was purchased from Dow Corning 
Corporation (Midland, MI). The liquid silicone rubber was 
gelatinous at room temperature (20°C). Vulcanized at 160°C   
with a heating duration of 200 seconds, the material became 
semisolid elastic rubber.
The rabbit FCVB was fabricated using injection-molding 
technology in a specially designed mirror steel mold. The core 
of the mold precisely mimics the shape of the vitreous body 
of the rabbit. The gaps in the mold control the thickness of 
the capsular film to as thin as 30 µm.19
Levofloxacin released in vitro
Levofloxacin powder (Livzon Pharmaceutical Group Inc, 
Zhuhai, Guangdong, China) was dissolved aseptically in 
distilled water (H2O) to a final concentration of 500 µg/mL. 
In vitro, 1.0 mL of this solution was injected into the capsules 
of the rabbit FCVB and these FCVBs were then immersed in 
cups of modified Franz diffusion cells. Following this, 200 µL 
of the liquid in each cup was aspirated for measurement at 10, 
20, and 40 minutes and 1, 6, 9, 12, and 24 hours (Figure 1). 
The levofloxacin content in the liquid was then detected by 
sensitive high-performance liquid   chromatography–tandem 
mass spectrometry (HPLC-MS/MS) (Thermo Finnigan LLC, 
San Jose, CA).
Levofloxacin released in vivo
For the in vivo study, the capsule was folded and implanted 
into the vitreous cavity after pars plana vitrectomy (PPV), 
then levofloxacin 1.0 mL (500 µg/mL) was injected into the 
capsule (Figure 2). In the control group, levofloxacin was 
injected into the vitreous cavity of three rabbits after PPV . 
The aqueous humor was aspirated on days 1, 7, 14, 28, and 
56 after implantation. The levofloxacin concentrations in the 
aqueous humor were detected by the HPLC-MS/MS method. 
All experimental procedures adhered to the Association for 
Research in Vision and Ophthalmology Resolution on the 
Use of Animals in Ophthalmic and Vision Research. The care 
of animals involved in experiments was in accordance with 
the guidelines of the Zhongshan Ophthalmic Center.
Before all surgical procedures, five New Zealand albino 
rabbits weighing 2.0–2.5 kg were anesthetized by an intra-
muscular injection of ketamine hydrochloride (30 mg/kg) and International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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chlorpromazine hydrochloride (15 mg/kg). Pupils were dilated 
with 0.5% tropicamide (Shenyang Xingqi Pharmaceutical Co, 
Ltd, Shenyang, China). PPV was performed, and the FCVB 
was implanted in the right eyes of the rabbits. A standard 
three-port PPV was performed on the right eye of each rabbit 
using a vitrectomy machine (Geuder, Heidelberg, Germany). 
After the vitrectomy, the capsule was folded and implanted into 
the vitreous cavity after a fluid-air exchange.   Approximately 
1.0 mL of levofloxacin (500 µg/mL) was injected into the 
capsule through a silicone tube-valve system, and thus the 
capsule was inflated to support the retina. The tube was 
subsequently fixed under the conjunctiva. The operation 
concluded with a subconjunctival injection of gentamicin 
and   dexamethasone and with the application of compound 
tobramycin and   atropine (1%) ointment. The animals were 
anesthetized on days 1, 7, 14, 28, and 56 after implantation, 
and 0.1–0.2 mL of aqueous humor was aspirated from both 
eyes of each rabbit. The aqueous humor samples were exam-
ined by the sensitive HPLC-MS/MS method.
Levofloxacin sample assay
The HPLC-MS/MS system consists of a Surveyor MS 
Pump and Autosampler (Thermo Finnigan) and a TSQ 
Quantum triple quadrupole mass spectrometer (Thermo 
Finnigan) equipped with an ESI source (Thermo Finnigan). 
A reversed-phase column XTerra C18 (3 mm × 150 mm, 
3.5 µm; Waters Corporation, Milford, MA) was used for all 
chromatographic separation at room temperature (20°C).   
For the levofloxacin sample in vitro, the mobile phase 
(1% formic acid in H2O and acetonitrile, 40:60, v/v) was 
N
N N
O
O
COOH
CH3
F
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FCVB + levofloxacin
Chemical structure of levofloxacin
H2O
A
BC
Figure 1 (A) Rabbit foldable capsular vitreous body (FCVB) filled with levofloxacin was immersed in cups of modified Franz diffusion cells, (B) a simple diagram of the 
releasing cell, and (C) the chemical structure of levofloxacin.
AB
CD
FCVB is folded
Valve of FCVB
Figure  2  Rabbit  foldable  capsular  vitreous  body  (FCVB)  with  levofloxacin  was 
implanted in vivo. (A) Pars plana vitrectomy was performed on the right eye, (B) the 
capsule of FcVB was folded, (C) FcVB was implanted into the vitreous cavity, and 
(D) levofloxacin solution was injected into the capsule through the valve.International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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pumped at a flow rate of 0.3 mL/min. For the levofloxacin 
sample in vivo, the mobile phase (1% formic acid in H2O 
and formic acid, 75:25, v/v) was pumped at a flow rate of 
0.2 mL/min. The mass spectrometer was operated in the 
positive electrospray ionization mode. Quantification was 
performed using selected reaction monitoring (SRM) in the 
positive mode. The ion transition of the mass-to-charge ratio 
(m/z) 361.7 → 318.0 for levofloxacin was monitored, with a 
collision-induced energy of 18 eV .
The reference formulation of levofloxacin (purity of 
99.99%, lot number 30537-200301) was obtained from the 
National Institute for the Control of Pharmaceutical and Bio-
logical Products, China. Acetonitrile and methanol of HPLC 
grade were purchased from SK Chemicals, Korea. Formic 
acid of HPLC grade was purchased from Merck (State Food 
and Drug Administration, Guangzhou, China).
The stock solutions were prepared in methanol at a 
concentration of 20 µg/mL in 100 mL glass vials and were 
serially diluted with methanol to prepare standard working 
solutions at the desired concentrations: 5, 10, 50, 100, 500, 
800, and 1000 ng/mL. From there, 30 µL samples were trans-
ferred into 2.0 mL Eppendorf tubes. After adding 30 µL of 
Cip solution (IS), 30 µL of methanol, and 300 µL of mobile 
phase, the mixture was vortexed for 1 minute and centrifuged 
at 12,000 rpm for 5 minutes. Approximately 0.1 mL of the 
supernatant was transferred into autosampler vials, and then 
10 µL was injected into the HPLC column. Data acquisi-
tion was performed with Xcalibur software (v 1.3; Thermo 
Finnigan). Peak integration and calibration were performed 
using LCquan software (v 1.3; Thermo Finnigan).
scanning electron microscopy  
of the FcVB
The capsules of the rabbit FCVB were observed under a 
scanning electron microscope (ESEM XL-30; Philips, the 
Netherlands) before and after these release studies. The 
capsules were cut to the appropriate size, and the visible 
surface of each sample was cleaned and coated with aurum 
by sputter coating (BAL-TEC SCD 005, Bal-Tec Co, Balzers, 
Liechtenstein) at 30 mA for 90 seconds. Samples were fixed 
on a specimen stub and images of the surface of each speci-
men were captured on the scanning electron microscope.
Results
The standard weight of the rabbit FCVB was 0.21 ± 0.005 g, 
and the standard volume was 1.0 ± 0.5 mL. The FCVB was 
transparent with light transmittance levels as high as 92%, 
and the thickness of the capsule was 60 µm (Figure 3).
The representative mass spectra of levofloxacin, HPLC-
MS/MS chromatograms, accuracy, and precision of the 
quality control (QC) samples are shown in Figures 4 and 5 
and in Table 1. Levels of levofloxacin released in vitro and 
in vivo are shown in Figures 6 and 7.
The HPLC-MS/MS parameters were optimized to pro-
duce the maximum response for levofloxacin in the positive 
ion mode. After electrospray ionization, positive ion frag-
ments of m/z 361.7 were detected in the SRM mode with a 
triple quadrupole mass spectrometer, and the fragment ions 
of m/z 318.0 were chosen as the production for monitoring 
levofloxacin. Fragment ions of m/z 332.2 → 314.0 were 
chosen for internal standard ciprofloxacin (Figure 4).
In representative HPLC-MS/MS chromatograms, H2O 
as a background solvent does not interfere with the channel 
of levofloxacin. Retention time of ciprofloxacin was 
2.25 minutes. This internal standard ciprofloxacin achieves 
the baseline separation with the impurities in H2O and does 
not interfere with the channel of levofloxacin. Retention time 
of levofloxacin was 2.2 minutes, thus achieving the baseline 
separation with the impurities in H2O (Figure 5).
The accuracy (relative error [RE], %) and precision (rela-
tive standard deviation [RSD],%) results for the QC samples 
are summarized in Table 1. The results of RE # ±15% and 
RSD # ±15% proved the acceptable level of accuracy and 
precision of the proposed method.
Rabbit FCVB can release levofloxacin in vitro. The results 
showed that the released levofloxacin was 20 ng/mL at the 
10-minute time point and then stabilized as 20 ng/mL over 
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Figure 3 steel mold and production of rabbit foldable capsular vitreous body (FcVB). 
(A) The mold for rabbit FcVB consisted of a core and lower and upper dies, 
(B) fabricated rabbit FcVB, and (C) the rabbit FcVB is highly transparent.International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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Figure 4 The production mass spectra of abundant protonated molecular ions ([M+h]+) for levofloxacin and ciprofloxacin. (A) Fragment ions of mass-to-charge ratio (m/z) 
362.0 → 318.1 were chosen as the production for monitoring levofloxacin and (B) fragment ions of m/z 332.2 → 314.0 were chosen for ciprofloxacin.
the following observation period (Figure 6). The relationships 
between concentration (Q) and time (t1/2) were described with 
Higuchi equation: Q = −0.113t1/2 + 20.01 (r = 0.625). The 
concentrations at different time points showed no significant 
difference (F = 4.366; P . 0.05) (Table 2).
Rabbit FCVB can release levofloxacin in vivo. On the 
first day after rabbit FCVB implantation, the levofloxacin 
concentration in the aqueous humor was 132 ng/mL. On 
days 7, 14, and 28, the levofloxacin was sustained as 50, 39 
and 11 ng/mL, respectively. Levofloxacin was still detectable International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
6
Jiang et al
5.74
5.61
5.51
5.30
4.94
4.53
4.46
4.37
4.30
4.01
3.95 3.51
3.23
2.94
2.80
2.53 0.49 0.15 0.72
1.01
1.41
2.14
1.73
2.20
H2O
Levofloxacin
0.37 0.11 0.48 0.60 1.00 1.34 1.59 1.74 2.13 2.24 2.59 2.83 2.99 3.28 3.60 3.77 4.20 4.96 5.19 5.54 5.69 5.94
4.44 NL:
3.88E3
TICF: +c
sid = −10.00 SRM
ms2
332.10@−22.00
[313.95-314.05]
MS b-01
NL:
5.46E1
TICF: +c
sid = −10.00 SRM
ms2
361.70@−18.00
[317.95−318.05]
MS b-01
0.0
0
10
20
30
40
50
60
70
80
90
100
0
10
20
30
40
50
60
70
80
90
100
RT: 0.00 – 6.00
1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0
Time (min)
1.0 0.5
R
e
l
a
t
i
v
e
 
a
b
u
n
d
a
n
c
e
A
0.22
0.21
0.29
0.46
0.67
0.76
2.23
2.40
2.81
2.93
3.60 3.71
3.77
3.85
4.14
4.20
4.26 4.73
4.80
4.95
5.21
5.44 5.64
5.97
1.34
1.18
0.57 0.75 0.85 1.14 1.33 1.63
1.59
2.25
2.74 3.33 3.52 3.71 3.97 4.23 5.34 5.60 5.10 5.71
4.60
3.05
NL: 7.71E3
TIC F: +c
sid = −10.00 SRM
ms2
332.10@−22.00
[313.95–314.05]
MS is-01
NL: 2.18E1
TIC F: +c
sid = −10.00 SRM
ms2
361.70@−18.00
[317.95–318.05]
MS is-01
0.0
0
10
20
30
40
50
60
70
80
90
100
0
10
20
30
40
50
60
70
80
90
100
RT: 0.00 – 6.00
1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5
Time (min)
6.0 1.0 0.5
Ciprofloxacin
R
e
l
a
t
i
v
e
 
a
b
u
n
d
a
n
c
e
Levofloxacin
B
Figure 5 representative high-performance liquid chromatography–tandem mass spectrometry chromatograms of (A) blank water (h2O), (B) blank h2O with internal 
standard ciprofloxacin, and (C) blank h2O with a sample of levofloxacin.
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at 15 ng/mL on day 56. In the control group, the levofloxa-
cin was 183 and 9 ng/mL on days 1 and 7 after intravitreal 
injection. The levofloxacin could not be detected on day 14 
(Figure 7).
In the scanning electron microscope images, numerous 
300 nm-mm apertures were observed in the capsule of the 
rabbit FCVB at the beginning and end of the observations, 
as shown in Figure 8.
Discussion
Endophthalmitis is defined as any inflammation of the 
internal ocular spaces, and it potentially results in poor visual 
prognoses for the majority of patients.4 An intravitreal DDS 
is the consensus ideal method for drug administration into 
the vitreous body.15 This study demonstrates that the rabbit 
FCVB can sustainably and mechanically release levofloxacin 
in vitro and in vivo and it may provide a new combined 
research and therapy strategy as a vitreous substitute and 
DDS for the treatment of bacterial endophthalmitis.
The use of levofloxacin for endophthalmitis has been pre-
viously described by Jackson et al,4 Herbert et al,22 Yildirim 
et al,12 Ferrer et al,8 and Gurler et al.23 Jackson et al,4 after 
reviewing 267 reported cases, demonstrated that the most 
common Gram-positive organisms are Staphylococcus aureus 
and Streptococcus pneumoniae. Herbert et al22 reported that 
levofloxacin possesses a wide spectrum in vitro against both 
Gram-positive and Gram-negative pathogens and suggested 
that the minimum inhibitory concentration required to inhibit 
the growth of 90% of the organisms (MIC90) for S. aureus is 
0.25–0.50 µg/mL. Yildirim et al12 demonstrated that intra-
vitreal levofloxacin appeared to be effective in S. epidermidis 
endophthalmitis in rabbits and that the culture results of the 
treatment groups were sterile. Gurler et al23 established the 
level of toxicity of intravitreal levofloxacin; the doses of 50, 
100, 250, and 500 µg in 0.1 mL injected into the mid-vitreous 
of rabbits were not toxic to the retina.
In this study, rabbit FCVB was demonstrated to 
have a sustained release of levofloxacin in vitro and 
in vivo: 300 nm-mm apertures in the capsule gave the 
FCVB the capability of a DDS. The formation of 300 nm 
apertures is attributed to the fabrication of FCVB. The 
liquid silicone rubber was injected into the mold at room 
temperature (20°C), and became semisolid elastic rubber 
after vulcanization. During vulcanizing, air traverses the 
silicone rubber membrane and leaves nanometer-grade 
channels. As the molecular mass of levofloxacin is 415.85 
daltons, the drug molecules will diffuse freely through 
0.00
10 min 20 min 40 min 1 h2  h3  h4  h5  h6  h9  h
T
C
 
(
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L
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Figure 6 The levofloxacin released from the foldable capsular vitreous body stabilized at 20 ng/mL in vitro.
Abbreviations: c, concentration; T, time.
Table 1 summary of accuracy and precision of quality control 
samples  in  high-performance  liquid  chromatography–tandem 
mass spectrometry detection
Added (ng/mL) Found (ng/mL) SD (%) RSD (%) RE (%)
10.00 11.43 0.72 6.73 7.00
10.68
9.99
100.00 107.59 7.76 7.41 4.66
95.87
110.53
800.00 854.21 57.66 7.31 −1.93
767.29
745.13
Linear equation Y = −0.0067 + 0.0085X
correlation  
coefficient (r2)
0.9936
Abbreviations: re, relative error; rsD, relative standard deviation; sD, standard 
deviation.International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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the apertures. The osmotic pressure, as long as the rabbit 
FCVB with levofloxacin is immersed in H2O, forces the 
levofloxacin molecules to move through the apertures to the 
outer circumstance. In this study, levofloxacin was shown 
to keep on releasing in vitro. On the other hand, the number 
of apertures also restricts the total flow rate and limits the 
rapid loss of the levofloxacin, and then a sustained drug 
release is achieved. Especially in vivo, as the released 
levofloxacin is taken away by blood, or metabolized 
quickly, osmotic pressure maintains the strain. Ohkubo 
et al24 demonstrated that the levofloxacin concentration was 
not detectable 1 week after the intravitreal injection in the 
choroid-retinal pigment epithelium of albino rabbits. In the 
present study, levofloxacin was still detectable 8 weeks 
after FCVB implantation.
Intraocular DDS is becoming increasingly important. 
The need for intraocular DDS has resulted in a variety of 
controlled-release systems such as implantable devices and 
injectable particles.15,16 Current DDSs such as the dexa-
methasone intravitreal implant for macular edema and the 
intravitreal fluocinolone acetonide implant for uveitis25,26 
have some major disadvantages; for example, they are 
opaque, they may interfere with vision, or they may result 
in a nonuniform drug distribution.15,16 In contrast, FCVB has 
good transparency, induces very little refractive shifts, and 
permits the levofloxacin in solution to disperse evenly in the 
capsule and to permeate the outside uniformly. In addition, 
different drugs could dissolve in this uniform FCVB, and no 
corresponding carrier is needed.
The authors’ previous studies have shown that the FCVB 
releases DexP in a time-dependent manner in vitro. In this 
study, levofloxacin released from the FCVB was stabilized 
at 20 ng/mL in vitro. The reason may be related to the dif-
ferent molecular weights and osmotic pressures of these 
two drugs. The molecular weight of DexP is 516.41 daltons; 
levofloxacin is 415.85 daltons. Solution osmotic pressures 
of these two drugs are also different: the solvent for DexP 
is saline, with an osmotic pressure of 1552.7 mOsm/kg; the 
solvent for levofloxacin is sterile H2O, and the osmotic pres-
sure is 2 mOsm/kg.
The dosage of levofloxacin released from the rabbit 
FCVB, at 6 hours in vitro and first day in vivo, are not as high 
as the MIC90 requirement for staphylococcus (0.25 µg/mL). 
The volume of the human vitreous body is about 4.0 mL, 
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Figure  8  scanning  electron  microscope  images  of  the  capsule  of  the  foldable 
capsular vitreous body where (A) 300 nm-mm apertures were observed in the 
capsule before release study and (B) apertures were observed at the end of release 
study.
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Figure 7 Foldable capsular vitreous body (FCVB) continuously released levofloxacin in vivo. The levofloxacin in the aqueous humor was 132, 50, 39, 11, and 15 ng/mL 
on days 1, 7, 14, 28, and 56, respectively, after rabbit FCVB implantation. In the control group, the levofloxacin was 183, 9, and 0 ng/mL on days 1, 7, and 14, respectively. 
Abbreviations: c, concentration; d, days; PPV, pars plana vitrectomy; T, time.
Table 2 The model fitting results for levofloxacin release from 
the foldable capsular vitreous body in vitro
Kinetic  
model
Equation r
Zero Q = −0.002t + 19.17 0.604
First order ln(100−Q) = −0.00003t + 4.392 0.602
higuchi Q = −0.113t1/2 + 20.01 0.625
Abbreviations: t, time; Q, concentration; r, correlation coefficient.International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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and the direct intravitreal injection of 500 µg/mL/0.1 mL 
levofloxacin was approximately 125 µg/mL. However, in 
eyes without PPV surgeries, levofloxacin is centralized and 
has to pass the vitreous body to the retina. In eyes after PPV , 
levofloxacin touches the retina directly. Other research on a 
rabbit FCVB demonstrated that in the S. aureus endophath-
almitis rabbit model the FCVB with 625 µg/mL levofloxacin 
tamponade, and the culture results of the aqueous humor 
were sterile (Figure 9).
Recently, a clinical trial on the biocompatibility and 
effectiveness of a FCVB as a silicone oil substitute in human 
eyes has been completed at Zhongshan Ophthalmic Center. The 
Sun Yat-sen University Medical Ethics Committee approved 
the clinical trials (Zhongshan Ophthalmic Center Medical 
Ethics (2009) No. 07); the trials have been successfully 
registered with ClinicalTrials.gov (ID: NCT00910702) and in 
the Chinese Clinical Trial Register (ChiCTR-TNC-00000396). 
The results showed that the FCVB was a flexible, effective, and 
safe vitreous substitute over a 3-month implantation period.20 
Thus, the FCVB may provide a combined vehicle for a vitreous 
substitute and an endophthalmitis DDS.
Because of the presence of the blood-ocular barrier, a 
plasma drug has difficulty entering the eye. In addition, eye 
drugs also have difficulty entering the plasma. In this study, 
levofloxacin release in the eye was 10–130 ng/mL, so there 
was no measurement of levofloxacin in the plasma.27,28 Future 
research should focus on the effect of human FCVB com-
bined with levofloxacin on human bacterial endophthalmitis 
in vitro and in vivo. Also, research studies on the investiga-
tion of other drugs are in progress, including antibiotics, 
antiproliferation agents, and vascular endothelial growth 
factor antagonists.
Conclusion
In conclusion, the rabbit FCVB released levofloxacin stably 
in vitro and sustainably released levofloxacin in vivo. FCVB 
combined with levofloxacin may provide a novel research 
and therapy strategy as a vitreous substitute and as a DDS 
for the treatment of bacterial endophthalmitis.
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